Hepatitis C in the Prisons environment – a round up of research

As 2020 drew to a close, INHSU Prisons was aware that many in the network were on the front line of the response to COVID-19, and often unable to stay up-to-date with the most recent publications relating to hepatitis C and prisons.

As such, INHSU Prisons put together a list of the most relevant publications in the 2019-20 year which can now be downloaded from the link below. 


Click here to download the full list of publications


Articles of outstanding interest

Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A.
J Hepatol. 2019 May;70(5):839-846. doi: 10.1016/j.jhep.2019.01.012. Epub 2019 Jan 14.
Summary: DAAs were delivered effectively and in high numbers in 14 adult prisons in Victoria, Australia using a nurse-led model of care, suggesting that decentralized HCV care could be considered for prison settings. 
Assoumou SA, Tasillo A, Vellozzi C, Eftekhari Yazdi G, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP.
Clin Infect Dis. 2020 Mar 17;70(7):1388-1396. doi: 10.1093/cid/ciz383.
Summary: Although expensive, adopting universal HCV testing and treatment in US prisons is cost-effective. 
Mohamed Z, Al-Kurdi D, Nelson M, Shimakawa Y, Selvapatt N, Lacey J, Thursz MR, Lemoine M, Brown AS.
Int J Drug Policy. 2020 Jan;75:102608. doi: 10.1016/j.drugpo.2019.102608. Epub 2019 Nov 20.
Summary: A higher proportion of English remand inmates were screened and treated within a shorter time period with a simplified test (Oraquick salivary) and treat strategy compared to standard of care (opt-out dried blood spot testing), underscoring that scaling up DBS screening and treatment in England may be sub-optimal for HCV elimination. 
Thank you! Your subscription has been confirmed. You'll hear from us soon.
Sign up to our monthly newsletter